Companies / Japan
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
Speculation Mounts Over Mitsubishi/Tanabe Merger
January 2007 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
Local press, analysts and the companies themselves have increasingly commented on the possible integration of Japanese drugmakers Mitsubishi Pharma and Tanabe Seiyaku. Tanabe would acquire Mitsubishi and parent company Mitsubishi Chemical would then take a controlling stake in the combined company. BMI believes that the possibility of a merger is strong because of the obvious benefits. Pressure to consolidate in Japan's pharmaceutical market is intense as R&D costs continue to increase, competition from foreign firms grows and the government pushes for lower healthcare costs for its rapidly ageing population.